Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: CPAMarty who wrote (600)	3/31/1999 8:26:00 PM
From: Market Tracker	Read Replies (3) \| Respond to of 2515

It looks as though Franklin Biotechnology Discovery Fund (FBDIX), had some nice things to say about IMCL this evening. cbs.marketwatch.com. Another hopeful is ImClone Systems Inc. (IMCL). The company is scheduled to present data on treatment for head and neck cancer at American Society of Clinical Oncology conference in May. "When you add their drug to chemotherapy in head and neck cancer, the response rate is close to or above 90 percent," von Emster says. "These are patients in whom cancers grow regardless of how they've been treated. When the drug is added, all of sudden the cancer responds and dies or becomes significantly reduced," he says. There's also a group of patients in that study in which cancer went away, von Emster says. Meaning, possibly, that there are some jewels strewn about the minefield.